Blueprint Medicines to Present New Clinical Data Across Broad Precision Therapy Pipeline at 2023 ASCO Annual Meeting

Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced acceptance of clinical abstracts for its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6. Highlights include the VELA trial results for BLU-222 in breast cancer, SYMPHONY trial updates on BLU-945 for EGFR-mutant non-small cell lung cancer (NSCLC), and BLU-451 trial results for EGFR exon 20 insertion-positive NSCLC. The data presentations aim to exhibit the safety and clinical efficacy of these therapies. Chief Medical Officer Becker Hewes emphasized the company's commitment to advancing innovative therapies to meet complex medical needs. These developments are part of the company's five-year growth strategy targeting broad patient populations.

Positive

• Acceptance of multiple clinical abstracts for ASCO highlights progress in therapeutic programs.
• Presentation of promising results from ongoing trials, indicating safety and efficacy of new drug candidates.
• Commitment to pioneering innovative treatment strategies and addressing complex medical needs.

Negative

• None.

CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6. The presentations showcase Blueprint Medicines' next wave of therapeutic candidates in its robust clinical pipeline, and highlight ongoing progress as the company seeks to pioneer innovative combination strategies and advance development of its programs into earlier lines of treatment.

The datasets to be reported at the ASCO Annual Meeting include:

• Results from the ongoing dose escalation part of the VELA trial of BLU-222 in breast cancer and other cancers vulnerable to CDK2 inhibition, showing evidence of monotherapy safety and pathway modulation.
  
  
• Updated results from the dose escalation part of the SYMPHONY trial showing the safety and tolerability of BLU-945 as a monotherapy and in combination with osimertinib in patients with late-line, EGFR-mutant non-small cell lung cancer (NSCLC).
  
  
• Results from the ongoing dose escalation part of the CONCERTO trial of BLU-451 in EGFR exon 20 insertion-positive NSCLC showing early safety and clinical activity.

"These upcoming presentations reflect important clinical progress toward realizing the promise of our innovative precision therapies to help address complex medical needs in lung and breast cancer, leveraging our scientific and development expertise with the goal of overcoming traditional limitations of targeted therapy," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "Collectively, the datasets represent another step toward achieving our 2027 Blueprint for Precision at Scale – our five-year growth strategy to reach broad patient populations through the development of transformative precision therapies."

The accepted abstracts are listed below, and abstract titles are available today on the ASCO conference website: meetings.asco.org.

Data Presentations

Poster Presentation Title: BLU-222, an oral, potent and selective CDK2 inhibitor, in patients with advanced solid tumors: phase 1 monotherapy dose escalation
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Session Date & Time: Saturday, June 3, 2023 from 8:00 a.m. — 11:00 a.m. CT (9:00 a.m. — 12:00 p.m. ET)
Abstract Number: 3095
Location: Hall A

Poster Presentation Title: Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Date & Time: Sunday, June 4, 2023 from 8:00 a.m. — 11:00 a.m. CT (9:00 a.m. — 12:00 p.m. ET)
Abstract Number: 9064
Location: Hall A

Short Oral Presentation Title: BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study
Session Title: Rapid Abstract Session: Lung Cancer
Session Date & Time: Monday, June 5, 2023 from 11:30 a.m. — 12:30 p.m. CT (12:30 p.m. — 1:30 p.m. ET)
Abstract Number: 9011
Location: S406

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' current or future approved drugs and drug candidates, including the results of ongoing clinical trials; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' financial performance, growth strategy, goals and anticipated milestones, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the COVID-19 pandemic may impact Blueprint Medicines' business, operations, strategy, goals and anticipated milestones, including ongoing and planned research and discovery activities, Blueprint Medicines' ability to conduct ongoing and planned clinical trials; the risk of delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; risks related to Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; preclinical and clinical results for Blueprint Medicines' drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates may be delayed or slower than anticipated; actions of regulatory agencies may affect the initiation, timing and progress of clinical trials; risks related to Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing; and the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

Trademarks

Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-new-clinical-data-across-broad-precision-therapy-pipeline-at-2023-asco-annual-meeting-301807634.html

SOURCE Blueprint Medicines Corporation

FAQ

What clinical data will Blueprint Medicines present at ASCO 2023?

Blueprint Medicines will present data from the VELA trial of BLU-222, SYMPHONY trial of BLU-945, and CONCERTO trial of BLU-451.

When will Blueprint Medicines' presentations take place during the ASCO Annual Meeting?

Presentations are scheduled for June 3-5, 2023, at various times.

What is the significance of the results from the VELA trial?

The VELA trial results demonstrate evidence of monotherapy safety and pathway modulation in patients with breast cancer.

How is the SYMPHONY trial relevant for patients with non-small cell lung cancer?

The SYMPHONY trial shows the safety and tolerability of BLU-945 as a monotherapy and in combination with osimertinib for late-line EGFR-mutant NSCLC.

What are Blueprint Medicines' long-term goals related to its clinical trials?

The company aims to achieve its 2027 Blueprint for Precision at Scale by developing transformative precision therapies for broad patient populations.